Cited by 5,261Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

Open access

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group·1998·New England Journal of Medicine

DOI 10.1056/nejm199811053391902

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. METHODS: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. RESULTS: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P<0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199811053391902

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Is Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded?: Findings in 356 222 Primary Screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
Stamler, J. (1986) · JAMA · doi:10.1001/jama.1986.03380200061022 · Cited by 1,318
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 665
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537

Show all 21 references

Research works printed but not linked: 4

Peto R, 1985, Circulation, 72, 451
Keech A, 1992, Postgrad Med J, 68, 870
1994, Lancet, 344, 1383
Keech A, 1998, Atherosclerosis, 136, S31

Sorted by citations

Items 201–300 of 1,037

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative
Culver, A. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.625 · Cited by 444
Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels: Subgroup Analyses in the Scandinavian Simvastatin Survival Study
Haffner, S. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2661 · Cited by 441
Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Antonopoulos, A. S., Margaritis, M., Lee, R., Channon, K. M., & Antoniades, C. A. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504803 · Cited by 440
Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439
Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 440
Lipoproteins, nutrition, and heart disease
Schaefer, E. J. (2002) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.2.191 · Cited by 436
Bone Marrow–Derived Progenitor Cells Modulate Vascular Reendothelialization and Neointimal Formation
Werner, N., Priller, J., Laufs, U., Endres, M., Böhm, M., Dirnagl, U., & Nickenig, G. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000036417.43987.d8 · Cited by 433
Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis
Rosenhek, R., Rader, F., Loho, N., Gabriel, H., Heger, M., Klaar, U., SCHEMPER, M., Binder, T. M., Maurer, G., & Baumgartner, H. (2004) · Circulation · doi:10.1161/01.cir.0000140723.15274.53 · Cited by 428
Guidelines for the management of chronic kidney disease
Levin, A., Hemmelgarn, B. R., Culleton, B. F., Tobe, S. W., McFarlane, P., Ruzicka, M., Burns, K. D., Manns, B., White, C., Madore, F., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080351 · Cited by 428
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D. J., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 427
Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000100688.17280.e6 · Cited by 424
Atherosclerotic Vascular Disease Conference
Faxon, D. P., Fuster, V., Libby, P., Beckman, J. A., Hiatt, W. R., Thompson, R. W., Topper, J. N., Annex, B. H., Rundback, J. H., Fabunmi, R. P., et al. (2004) · Circulation · doi:10.1161/01.cir.0000128520.37674.ef · Cited by 421
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
(2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.054 · Cited by 418
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
Ballantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., & Kjekshus, J. (2001) · Circulation · doi:10.1161/hc5001.100624 · Cited by 416
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients
Ko, D. T., Mamdani, M., & Alter, D. A. (2004) · JAMA · doi:10.1001/jama.291.15.1864 · Cited by 412
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 409
Prior Statin Therapy Is Associated With a Decreased Rate of Severe Sepsis
Almog, Y., Shefer, A., Novack, V., Maimon, N., Barski, L., Eizinger, M., Friger, M. D., Zeller, L., & Danon, A. (2004) · Circulation · doi:10.1161/01.cir.0000138932.17956.f1 · Cited by 405
Navigating the Crossroads of Coronary Artery Disease and Heart Failure
Gheorghiade, M., Sopko, G. S., Luca, L. D., Velazquez, E. J., Parker, J. D., Binkley, P. F., Sadowski, Z., Golba, K. S., Prior, D., Rouleau, J. L., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.623199 · Cited by 408
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations
Grundy, S. M., Pasternak, R. C., Greenland, P., Smith, S. C., & Fuster, V. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00387-3 · Cited by 403
Statin-Sensitive Dysregulated AT1 Receptor Function and Density in Hypercholesterolemic Men
Nickenig, G., Bäumer, A. T., Temur, Y., Kebben, D., Jockenhövel, F., & Böhm, M. (1999) · Circulation · doi:10.1161/01.cir.100.21.2131 · Cited by 394
Two decades of progress in preventing vascular disease
Yusuf, S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09358-3 · Cited by 390
Acute Coronary Syndromes: Diagnosis and Management, Part I
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.10.917 · Cited by 390
Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice
Laufs, U., Gertz, K. R., Huang, P. L., Nickenig, G., Böhm, M., Dirnagl, U., & Endres, M. (2000) · Stroke · doi:10.1161/01.str.31.10.2442 · Cited by 389
Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project
Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation · doi:10.1161/01.cir.102.16.1893 · Cited by 388
The Forgotten Majority
Libby, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.006 · Cited by 388
Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis
Janda, S., Shahidi, N. C., Gin, K. G., & Swiston, J. R. (2011) · Heart · doi:10.1136/hrt.2010.212084 · Cited by 384
OECD Study of Cross-National Differences in the Treatment, Costs and Outcomes of Ischaemic Heart Disease
Moïse, P., & Jacobzone, S. (2003) · OECD health working papers · doi:10.1787/230112362071 · Cited by 380
Coaching patients On Achieving Cardiovascular Health (COACH)
Vale, M. J., Jelinek, M. V., Best, J. D., Dart, A. M., Grigg, L., Hare, D. L., Ho, B. P., Newman, R. W., & McNeil, J. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.22.2775 · Cited by 379
Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability
Koh, K. K. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00146-2 · Cited by 379
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
Tonelli, M. A., Isles, C., Curhan, G. C., Tonkin, A. M., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C. D., Cobbe, S. M., Simes, J. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143892.84582.60 · Cited by 374
Primary Prevention of Ischemic Stroke
Goldstein, L. B., Adams, R. J., Becker, K. J., Furberg, C. D., Gorelick, P. B., Hádemenos, G. J., Hill, M., Howard, G., Howard, V. J., Jacobs, B. S., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.163 · Cited by 374
Vasoprotection by nitric oxide: mechanisms and therapeutic potential
Gewaltig, M. T. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00327-9 · Cited by 371
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review
Alloubani, A., Nimer, R. M., & Samara, R. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x16999201210200342 · Cited by 366
Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease
Schartl, M., Bocksch, W., Koschyk, D. H., Voelker, W., Karsch, K. R., Kreuzer, J., Hausmann, D., Beckmann, S., Gross, M. C., & for the German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN) (2001) · Circulation · doi:10.1161/hc2901.093188 · Cited by 364
Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome
Hiro, T., Kimura, T., Morimoto, T., Miyauchi, K., Nakagawa, Y., Yamagishi, M., Ozaki, Y., Kimura, K., Saito, S., Yamaguchi, T., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.033 · Cited by 358
Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy
Henderson, R. A., Pocock, S., Clayton, T. C., Knight, R., Fox, K. A. A., Julian, D. G., & Chamberlain, D. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00951-3 · Cited by 357
Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J. Q., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 357
Cardiac cachexia: A systematic overview
von Haehling, S., Lainščak, M., Springer, J., & Anker, S. D. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 356
Inflammatory Cytokines in Heart Failure: Mediators and Markers
Gullestad, L. L., Ueland, T., Vinge, L. E., Finsen, A. V., Yndestad, A., & Aukrust, P. (2012) · Cardiology · doi:10.1159/000338166 · Cited by 355
Our Reviewers
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 355
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318212bb8b · Cited by 352
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Preventing myocardial infarction in the young adult in the first place: how do the national cholesterol education panel iii guidelines perform?
Akosah, K. O., Schaper, A. M., Cogbill, C. H., & Schoenfeld, P. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00187-6 · Cited by 350
Guidelines for the management of arterial hypertension
van de Borne, P. (2014) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.2143/ac.69.1.3011345 · Cited by 349
Statins for Secondary Prevention in Elderly Patients
Afilalo, J., Duque, G., Steele, R. J., Jukema, J. W., de Craen, A. J. M., & Eisenberg, M. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.063 · Cited by 347
Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study
Holdaas, H., Fellström, B., Cole, E., Nyberg, G., OLSSON, A. G., Pedersen, T. R., Madsen, S., Grönhagen‐Riska, C., Neumayer, H. ‐., Maes, B., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01105.x · Cited by 346
Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association
Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 345
Exercise training intervention after coronary angioplasty: the ETICA trial
Belardinelli, R., Paolini, I., Cianci, G., Piva, R., Georgiou, D., & Purcaro, A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01236-0 · Cited by 342
Beyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342
Preventing Ischemic Stroke in Patients With Prior Stroke and Transient Ischemic Attack
Wolf, P. A., Clagett, G., Easton, J. D., Goldstein, L. B., Gorelick, P. B., Kelly‐Hayes, M., Sacco, R. L., & Whisnant, J. P. (1999) · Stroke · doi:10.1161/01.str.30.9.1991 · Cited by 342
Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure
Horwich, T. B., MacLellan, W. R., & Fonarow, G. C. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.049 · Cited by 341
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340
Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy
Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.064 · Cited by 340
Acute Coronary Syndromes: Diagnosis and Management, Part II
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60674-5 · Cited by 340
Sensitivity and Specificity of the Ankle–Brachial Index to Predict Future Cardiovascular Outcomes
Doobay, A. V., & Anand, S. S. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000168911.78624.b7 · Cited by 339
STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)
Montalescot, G., Dallongeville, J., BELLE, E. V., Rouanet, S., Baulac, C., Degrandsart, A., Vicaut, É., & for the OPERA Investigators (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm031 · Cited by 339
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials
Mills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338
PCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
Non-lipid-related effects of statins
Bellosta, S., Fed, N., Bernini, F., Paoletti, R., & Corsini, A. (2000) · Annals of Medicine · doi:10.3109/07853890008998823 · Cited by 338
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 336
Pravastatin Therapy and the Risk of Stroke
White, H. D., Simes, R. J., Anderson, N. E., Hankey, G. J., Watson, J. D. G., Hunt, D., Colquhoun, D. M., Glasziou, P., MacMahon, S. W., Kirby, A. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430502 · Cited by 335
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Interventions to improve adherence to lipid-lowering medication
van Driel, M. L., Morledge, M. D., Ulep, R., Shaffer, J. P., Davies, P., & Deichmann, R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004371.pub4 · Cited by 333
Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 331
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)
Strandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 329
Impact of inactivity and exercise on the vasculature in humans
Thijssen, D. H. J., Maiorana, A., O’Driscoll, G., Cable, N. T., Hopman, M. T. E., & GREEN, D. J. (2009) · European Journal of Applied Physiology · doi:10.1007/s00421-009-1260-x · Cited by 324
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure
Sola, S., Mir, M. Q. S., Khan, B. V., Lerakis, S., & Tandon, N. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.088 · Cited by 322
Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
van Heek, M., Farley, C., Compton, D. S., Hoos, L. M., Alton, K. B., Sybertz, E. J., & Davis, H. R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703235 · Cited by 322
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Suboptimal statin adherence and discontinuation in primary and secondary prevention populations
Ellis, J. J., Erickson, S. R., Stevenson, J. G., Bernstein, S. J., Stiles, R. A., & Fendrick, A. M. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30516.x · Cited by 320
Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction
Serban, M.-C., Colantonio, L. D., Manthripragada, A. D., Monda, K. L., Bittner, V. A., Banach, M., Chen, L., Huang, L., Dent, R., Kent, S. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.036 · Cited by 318
Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
Eddy, D. M., Schlessinger, L., & Kahn, R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00006 · Cited by 318
Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy
Raggi, P., Callister, T. Q., & Shaw, L. J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000127024.40516.ef · Cited by 318
Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane, S. I., Muniyappa, R., Francisco, R., & Sowers, J. R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8412 · Cited by 317
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316
HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study
Després, J., Lemieux, I., Dagenais, G. R., Cantin, B., & Lamarche, B. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00603-1 · Cited by 316
Dyslipidaemia
Durrington, P. N. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14234-1 · Cited by 316
Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction
Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O. A., Morgan, J. M., & Capuzzi, D. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.056 · Cited by 315
Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage
McWilliams, J. M., Meara, E., Zaslavsky, A. M., & Ayanian, J. Z. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-8-200904210-00005 · Cited by 315
Statins in the primary prevention of cardiovascular disease
Reiner, Ž. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.80 · Cited by 314
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
Bays, H. E., Moore, P. B., Drehobl, M., Rosenblatt, S., Toth, P. D., Dujovne, C. A., Knopp, R. H., Lipka, L., LeBeaut, A., Yang, B., et al. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80102-8 · Cited by 314
Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose
Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2713 · Cited by 313
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
Kasiske, B. L., Cosío, B. G., Beto, J. A., Bolton, K., Chavers, B. M., Grimm, R. H., Levin, A., Masri, B. A., Parekh, R. S., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 313
High-Density Lipoprotein Cholesterol and Ischemic Stroke in the Elderly: The Northern Manhattan Stroke Study
Sacco, R. L., Benson, R. T., Kargman, D. E., Boden-Albala, B., Tuck, C., Lin, I.-F., Cheng, J. F., Paik, M. C., Shea, S., & Berglund, L. (2001) · JAMA · doi:10.1001/jama.285.21.2729 · Cited by 311
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.023 · Cited by 319
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
Aronow, H. D., Topol, E. J., Roe, M. T., Houghtaling, P. L., Wolski, K. E., Lincoff, A. M., Harrington, R. A., Califf, R. M., Ohman, E. M., Kleiman, N. S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04257-4 · Cited by 308
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. K. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 301
Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Predictors of late development of heart failure in stable survivors of myocardial infarction
Lewis, E. F., Moyé, L. A., Rouleau, J. L., Sacks, F. M., Arnold, J. M. O., Warnica, J. W., Flaker, G. C., Braunwald, E., & Pfeffer, M. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)01057-x · Cited by 304
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., Noorden, C. J. F. V., & Guchelaar, H. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 303
Meta‐analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes
Cheung, B. M. Y., Lauder, I. J., Lau, C., & Kumana, C. R. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02060.x · Cited by 303
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Abdul‐Ghani, M. A., Prato, S. D., CHILTON, R. J., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dc16-0041 · Cited by 303
Risk factors for coronary heart disease: implications of gender
van Lennep, J. R. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00388-1 · Cited by 302

Authors: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Affiliations: The University of Sydney (AU)
Corresponding author: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-11-05
Volume: 339
Issue: 19
Pages: 1349-1357
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199811053391902
OpenAlex: W38523360
Cited by: 5,261
References: 21
Citations by year: 2026: 19 · 2025: 24 · 2024: 57 · 2023: 53 · 2022: 60 · 2021: 58 · 2020: 72 · 2019: 82 · 2018: 81 · 2017: 94 · 2016: 114 · 2015: 111 · 2014: 118 · 2013: 167 · 2012: 147
FWCI: 312.19
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
UWA Profiles and Research Repository (UWA) (submittedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: pravastatin, coronary artery disease, statin therapy, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, coronary revascularization, total cholesterol, secondary prevention, lipid-lowering diet
MeSH terms: Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Mortality, Myocardial Infarction, Risk, Incidence, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks